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• Iron-deficiency anemia (IDA) is a leading cause of morbidity
and mortality in patients with CKD1,2

◦◦ eGFR >60 mL/min/1.73 m = mean hsCRP 1.75 mg/L
(95% CI 0.95–3.33) (p<0.001)
2

–– Intravenous iron administration can be inconvenient and
risks allergic reactions or iron overload3,4

Figure 1. Mechanism of action of oral ferric maltol

–– Oral ferrous treatments are associated with
gastroenterological adverse events that can significantly
impair compliance and efficacy5
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–– Some patients with CKD have chronic inflammation, which
can reduce the absorption and utilization of iron6
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• Ferric maltol is an oral iron-replacement therapy formulated to
improve gastrointestinal (GI) absorption (Figure 1)
• AEGIS-CKD was a phase III multicenter, randomized controlled
trial (NCT02968368) to evaluate the efficacy of oral ferric maltol
versus placebo in the treatment of IDA in adults with CKD
(Figure 2)

Intestinal lumen

Iron transporter
mechanism

Enterocyte

Ferric maltol is a complex of ferric iron (Fe3+) and three maltol ligands. Maltol
is a sugar derivative found in many food products; it strongly chelates iron in the
ferric form so that it is stable and available for absorption.
Before absorption, the ferric iron and maltol complex remains intact in the
intestinal lumen, minimizing the risk of GI toxicity associated with free radicals
produced by free iron. On absorption, ferric iron is bound to the iron transport
receptor, and the maltol complex dissociates to be rapidly absorbed by diffusion,
metabolized by glucuronidation, and eliminated by the kidneys.
Iron uptake with ferric maltol is saturable, avoiding the potential for iron
overload. Unabsorbed ferric maltol is excreted intact in feces.

–– CRP is notably higher in patients with CKD than in patients
with less kidney impairment:7
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BID, twice daily; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; R, randomization; TSAT, transferrin saturation.
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• hsCRP subgroups were based on the standard ranges for
cardiovascular risk: low (<1 mg/L), moderate (≥1 to ≤3 mg/L),
and high (>3 mg/L)

–– The least-squares mean (LSM) change from baseline was
determined by analysis of covariance with treatment as a
factor and continuous covariates of baseline Hb and eGFR
–– Changes in iron parameters were based on observed data,
with last observation carried forward (LOCF)

• 167 patients were randomized, 111 to ferric maltol and 56
to placebo (Table 1); all patients were included in the hsCRP
subgroup analysis

52

Demographic, n (%)
Age, years

Mean (SD)

Sex, n (%)

Female
Male

Primary efficacy endpoint
Change in Hb concentration
from baseline to week 16

Total
(n=167)

5

68.5 (12.4)

65.2 (12.8)

67.4 (12.6)

4

78 (70.3)

39 (69.6)

117 (70.1)

17 (30.4)

50 (29.9)

0

2 (1.2)

American Indian

1 (0.9)

0

1 (0.6)

African American

23 (20.7)

12 (21.4)

35 (21.0)

81 (73.0)

Other
Hb, g/dL

Placebo
(n=56)

2 (1.8)

White

4 (3.6)

Mean (SD)

42 (75.0)

123 (73.7)

2 (3.6)

6 (3.6)

10.06 (0.769) 10.03 (0.817) 10.05 (0.783)

<9.5, n (%)

21 (18.9)

11 (19.6)

32 (19.2)

≥9.5, n (%)

90 (81.1)

45 (80.4)

135 (80.8)

31.9 (11.53)

29.7 (10.56)

31.1 (11.23)

59 (53.2)

30 (53.6)

89 (53.3)

52 (46.8)

26 (46.4)

78 (46.7)

22 (19.8)

9 (16.1)

31

26 (23.4)

17 (30.4)

43

63 (56.8)

30 (53.6)

93

eGFR, mL/ Mean (SD)
min/1.73 m2
≤30, n (%)
>30, n (%
hsCRP range, <1 mg/L
n (%)
≥1 to ≤3 mg/L
>3 mg/L

• At week 16
–– All iron parameters were significantly improved with ferric
maltol vs placebo (abstract #FR-OR120)

°

Consistent results were seen regardless of degree of
underlying inflammation, as measured by baseline
hsCRP level (Figure 3)

–– The mean change from baseline in TSAT was 3.78%
(SD 0.638) with ferric maltol and –0.69% (SD 0.900) with
placebo (p<0.0001)
°

As with ferritin, consistent results were seen regardless
of degree of underlying inflammation (Figure 4)

Figure 3. Mean change in ferritin from baseline to week 16 by
hsCRP level at baseline (ITT population, LOCF)
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Figure 4. Mean change in TSAT from baseline to week 16 by
hsCRP level at baseline (ITT population, LOCF)
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–– 129 (77%) patients completed 16 weeks of treatment (19 [81%]
in the ferric maltol group and 39 [70%] in the placebo group)

–– The mean change from baseline in ferritin was 25.49 µg/dL
(SD 5.400) with ferric maltol and –8.25 µg/dL (SD 7.614)
with placebo (p=0.0004)

Figure 2. Study design

2

• Changes in iron parameters (ferritin, transferrin saturation
[TSAT], and serum iron) were assessed at weeks 4, 8, and 16

Results

–– Primary results for AEGIS-CKD will be presented separately
(abstract #FR-OR120); here we report changes in iron
storage indices for subgroups based on the degree of
chronic inflammation as assessed by high-sensitivity
C-reactive protein (hsCRP) levels

Key inclusion criteria:

• hsCRP was measured at baseline

• Analyses of change from baseline to week 16 were carried out
on the intent-to-treat (ITT) population (all randomized patients)

Maltol

• Patients with CKD and IDA would therefore benefit from an
oral iron-replacement therapy that is tolerable and effective
irrespective of the degree of underlying inflammation

Methods

Mean change from baseline
to week 16 (µg/L)

Background

Table 1. Patient demographics and baseline disease characteristics
(ITT population)

Ferric maltol
Placebo

25.32

23.78

Mean change from baseline
to week 16 (%)

◦◦ Estimated glomerular filtration rate (eGFR) <60 mL/
min/1.73 m2 = mean hsCRP 4.10 mg/L (95% confidence
interval [CI] 1.9–10.2)
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0
-5
-10

n=22

n=9
-3.67

n=26

n=17

n=63

n=30

-3.88

-15

-12.87

-20
<1 mg/L

≥1 to ≤3 mg/L
Baseline hsCRP level

>3 mg/L

n=30

-0.12

-1
-2

n=17

-0.97
-1.89

-3
<1 mg/L

≥1 to ≤3 mg/L

>3 mg/L

Baseline hsCRP level

Conclusion
• Ferric maltol improved iron storage parameters – ferritin and
TSAT – from baseline to week 16 vs placebo in patients with
IDA and CKD irrespective of the degree of underlying chronic
inflammation
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